A case report of QT prolongation with glycopyrronium bromide in a patient with chronic tamoxifen use

被引：2
作者：
Chiu M.H. [1 ]
Al-Majed N.S. [2 ]
Stubbins R. [3 ]
Pollmann D. [4 ]
Sandhu R.K. [2 ]
机构：
[1] Division of Cardiology, Libin Cardiovascular Institute, University of Calgary, Calgary, AB
[2] Division of Cardiology, University of Alberta, Edmonton, AB
[3] Department of Internal Medicine, Faculty of Medicine, University of Alberta, Edmonton, AB
[4] Department of Pharmacy, Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, AB
来源：
BMC Research Notes | / 9卷 / 1期
关键词：
Chronic obstructive pulmonary disease; Glycopyrronium bromide (Seebri); NVA237; QT prolongation;
D O I：
10.1186/s13104-016-2105-4
中图分类号：
学科分类号：
摘要：
Background: Glycopyrronium bromide has recently been approved as a once daily maintenance inhalation therapy for moderate to severe chronic obstructive pulmonary disease (COPD). Efficacy and safety trial data have found rare cases of significant QT prolongation. To our knowledge, we describe the first case report of QT prolongation >600 ms with initiation of glycopyrronium bromide in a real world setting. Case presentation: A 78-year-old female with moderate COPD recently started on glycopyrronium bromide, presented to Emergency Department (ED) with syncope. Her past medical history was significant for a left total mastectomy and she had been on Tamoxifen for 9 months. One day prior to her presentation, she had visited a naturopathic clinic for a vitamin infusion resulting in emesis. The following day she continued to feel dizzy and had a witnessed syncopal episode without any reported cardiac or neurological symptoms preceding the event or after regaining consciousness. In the emergency department, she reported dizziness and was found to be hypotensive. Her symptoms completely resolved with intravenous fluids. Lab work was normal however her electrocardiogram (ECG) demonstrated a QTc interval of 603 and 631 ms (Friderica and Bazett's respectively) with a normal QT interval on her baseline ECG prior to initiating Tamoxifen. She was admitted to the Cardiology service for further work-up of QT prolongation. Her syncope was felt to be due to orthostatic hypotension and the QT prolongation secondary to medications, which were both discontinued during her admission. After 2 days, her QT interval normalized consistent with the half-life of Glycopyrronium bromide (13-57 h) compared to Tamoxifen (8-14 days). Conclusion: Glycopyrronium bromide is guideline recommended as first line therapy for prevention of exacerbation in moderate to severe COPD however safety data had been limited to select populations. This case report highlights the need for future studies to identify high-risk populations at potential risk of life-threatening arrhythmias who may benefit from periodic ECG surveillance. © 2016 The Author(s).
引用
收藏
相关论文
共 20 条
[1]  
Rycroft C.E., Heyes A., Lanza L., Becker K., Epidemiology of chronic obstructive pulmonary disease: A literature review, Int J Chron Obstr Pulm Dis, 7, pp. 457-494, (2012)
[2]  
Prakash A., Babu K.S., Morjaria J.B., Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD, Int J Chron Obstruct Pulmon Dis, 10, pp. 111-123, (2015)
[3]  
Criner G.J., Bourbeau J., Diekemper R.L., Ouellette D.R., Goodridge D., Hernandez P., Curren K., Balter M.S., Bhutani M., Camp P.G., Et al., Prevention of acute exacerbations of chronic obstructive pulmonary disease: American college of chest physicians and canadian thoracic society guideline, Chest, 147, 4, pp. 894-942, (2015)
[4]  
D'Urzo A., Ferguson G.T., Van Noord J.A., Hirata K., Martin C., Horton R., Lu Y., Banerji D., Overend T., Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: The GLOW1 trial, Respir Res, 12, 1, (2011)
[5]  
Kerwin E., Hebert J., Gallagher N., Martin C., Overend T., Alagappan V.K.T., Lu Y., Banerji D., Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: The GLOW2 study, Eur Respir J, 40, 5, pp. 1106-1114, (2012)
[6]  
Beeh K.M., Singh D., Di Scala L., Drollmann A., Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: The GLOW3 trial, Int J Chron Obstruct Pulmon Dis, 7, pp. 503-513, (2012)
[7]  
Chapman K.R., Beeh K.-M., Beier J., Bateman E.D., D'Urzo A., Nutbrown R., Henley M., Chen H., Overend T., D'Andrea P., A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: The GLOW5 study, BMC Pulm Med, 14, (2014)
[8]  
Vincken W., Aumann J., Chen H., Henley M., McBryan D., Goyal P., Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: The GLOW6 study, Int J Chron Obstruct Pulmon Dis, 9, pp. 215-228, (2014)
[9]  
Sekiya M., Kawayama T., Fukuchi Y., Takahashi Y., Kaiso T., Ikeda K., Overend T., Banerji D., Safety and efficacy of NVA237 once daily in Japanese patients: The GLOW4 trial, Eur Respir J, 40, (2012)
[10]  
Drollmann A., Sechaud R., Pal P., Hara H., Uziel-Fusi S., Winkle P., Glycopyrronium does not affect QT interval in healthy subjects: A randomized, three-period, cross-over, placebo- and positive-controlled study, Int J Clin Pharmacol Ther, 52, 9, pp. 739-745, (2014)
12